year-earlier quarter) helped move net profit higher. The company's Eurex segment, which houses derivatives trading, continued to feel ..... conditions will improve in 2013, but in the early part of the year Eurex trading has tracked below 2012's daily average. It is still
revenue comes from the Over the Counter (OTC) Market. OTC trades differ from trading on a standardised exchange like NYSE or Eurex . OTC trades are characterised by low volume, very large deal size and non-standardisation. ICAP facilitates trades in many
FRANKFURT, Nov 15 (Reuters) - Deutsche Boerse said 10 banks, more than previously announced, backed the launch of a new platform for over-the-counter (OTC) interest rate swaps clearing ahead of regulation of the $700 trillion derivatives industry.
value estimate could go lower. The revenue decline was steep at Eurex , the company's derivatives operation and the largest contributor to Deutsche Boerse's top line. At Eurex , net revenue for the quarter dropped by about 26% to nearly EUR
FRANKFURT, Oct 1 (Reuters) - Deutsche Boerse is exploring an expansion into trading currency futures contracts, a source close to the company said on Monday, mirroring a similar push by arch-rival CME Group Inc..
fell by about 6% in Europe and by about 8% in Deutsche Boerse's U.S. options business. However, overall net revenue at Eurex --the largest of Deutsche Boerse's segments by top-line contribution--rose by about 7% to EUR 234.8 million as Deutsche
FRANKFURT, May 31 (Reuters) - Deutsche Boerse's Eurex Clearing unit will launch a platform for over-the-counter (OTC) interest rate swaps clearing in close cooperation with a group of banks ahead of...
577 million as trading activity at the Eurex segment climbed about 4% on a year-on-year ..... Annual sales growth was strongest at Eurex , where the top line rose about 10% and ..... made progress. The full acquisition of Eurex also will benefit the firm. Finally
contemplating other transactions. Looking further into 2012, Deutsche Boerse still has its acquisition of the remaining stake in Eurex to focus on, which we think will help the company's profitability. We also look ahead to the release of fourth-quarter
antitrust concerns of European regulators. The two also promise rivals better access to their clearinghouse, and will license the Eurex trading system to a 3rd party. Pfizer's Lipitor loses 15% market share. Pfizer's (PFE) Lipitor cholesterol pill lost